A naturally occurring neuropeptide that your body already produces, found in the hypothalamus, limbic system, pituitary, and even breast milk. DSIP (Delta Sleep-Inducing Peptide) was first isolated in 1974 by Swiss researchers who found it in the cerebral blood of sleeping rabbits, and it's named for its ability to promote deep, slow-wave (delta) sleep. Used for poor sleep quality, stress-driven insomnia, or you want to improve recovery by targeting the actual architecture of sleep rather than just knocking yourself out with melatonin or a sedative.
What makes DSIP interesting compared to other sleep interventions is that it doesn't sedate you. It works by enhancing your body's own sleep regulation systems, promoting the deep restorative phases of sleep where tissue repair, hormone secretion, and memory consolidation actually happen. It also modulates stress hormones, influences growth hormone and LH release, and has shown analgesic and antioxidant properties in research. DSIP's research base is limited, most human trials are small and date back to the 1980s, and its exact mechanism still isn't fully understood. No specific receptor or gene for DSIP has been identified in humans, which is unusual for a neuropeptide. That said, the effects reported in both clinical trials and anecdotal use are consistent enough that it's worth understanding.
DSIP is a simple nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) with a molecular weight of 850 daltons. Unlike most peptides, it freely crosses the blood-brain barrier and can even survive gut absorption without being fully denatured by enzymes, though its plasma half-life is short, around 15 minutes in vitro due to aminopeptidase activity. In the body, it likely complexes with carrier proteins to avoid rapid degradation, though the precursor molecule hasn't been identified.
In the pituitary, DSIP co-localises with ACTH, MSH, TSH, and melanin-concentrating hormone, which hints at why it affects so many hormonal systems simultaneously. Its mechanism appears to involve enhancing GABA signalling (the brain's main inhibitory, calming neurotransmitter) while blocking NMDA receptor activity (excitatory), essentially turning up the calm and turning down the noise.
Sleep: The core use case. DSIP doesn't work like a sleeping pill. It promotes slow-wave delta sleep, the deepest phase of sleep where your body does most of its physical repair and growth hormone release. An early human trial of six volunteers given intravenous DSIP found that subjects reported immediate sleep pressure, total sleep time increased by 59%, and subsequent night sleep showed shorter onset, reduced stage 1 sleep, and better efficiency, all without any classic sedation. A study on severe chronic insomniacs showed statistically significant improvements in sleep-wake behaviour over 24 hours. However, a double-blind study on 16 chronic insomniacs found that while sleep efficiency improved and sleep latency shortened compared to placebo, the effects were weak and short-term treatment was unlikely to provide major therapeutic benefit. The research is mixed but leans positive, particularly for people whose sleep is already disrupted rather than healthy sleepers.
An important nuance: DSIP given during the day can improve sleep that night and for several nights after. It's described in the literature as a sleep-promoting substance rather than a sedative, with a modulating effect on sleep and wake functions that shows greater activity when sleep is already disturbed. Minimal effects in healthy subjects who sleep fine.
Stress and HPA axis modulation: DSIP acts as what researchers call a "stress-limiting factor." It modulates the hypothalamic-pituitary-adrenal (HPA) axis by decreasing basal ACTH levels and blocking ACTH release under stress. Since ACTH tells the adrenals to produce cortisol, this translates to lower cortisol output. Research in humans showed a significant reduction in ACTH for at least 3 hours after DSIP injection compared to controls. Animal studies have shown approximately 30% reductions in stress-induced corticosterone. For anyone dealing with chronic stress, overtraining, or HPA axis dysfunction, this is the mechanism that makes DSIP more than just a sleep peptide. Chronic cortisol elevation wrecks sleep architecture, promotes visceral fat storage, accelerates muscle breakdown, and tanks immune function. By normalising cortisol, DSIP may address a root cause of poor sleep rather than just masking symptoms.
Hormonal effects: DSIP influences several hormonal systems beyond cortisol. It stimulates release of luteinizing hormone (LH), which in men signals testosterone production and in women supports ovulation and progesterone synthesis. In rat studies, intraventricular DSIP caused significant LH elevation within 30 minutes, persisting for 2 hours, and also produced dose-related increases in growth hormone release. It stimulates growth hormone-releasing hormone (somatoliberin) and GH itself while inhibiting somatostatin, which normally suppresses GH. For athletes and anyone interested in recovery, this hormonal profile, enhanced GH release during deeper sleep plus LH support, adds practical value beyond sleep quality alone. However, note that a study in women found no effect on GH or prolactin, suggesting the hormonal influence is selective and context-dependent.
Pain modulation: DSIP has demonstrated analgesic properties through a mechanism distinct from direct opioid receptor binding. It appears to work indirectly by stimulating release of met-enkephalin, one of the body's natural opioid peptides. A pilot study on 7 patients with chronic pain (migraines, vasomotor headaches, tinnitus, psychogenic pain) found significant pain reduction in 6 out of 7 after intravenous DSIP over consecutive days, along with a decrease in associated depressive states. Small sample size, but consistent with the mechanism.
Withdrawal support: One of DSIP's most striking findings. A clinical trial administered DSIP intravenously to 107 inpatients with alcohol or opiate withdrawal symptoms. In 97% of opiate-dependent and 87% of alcohol-dependent patients, withdrawal symptoms disappeared or improved markedly and rapidly. Anxiety resolved more slowly but still within hours. Tolerance to the treatment was good aside from headaches in a few patients. An earlier trial of 67 patients found similar results, with 48 out of 49 evaluable patients showing benefit with immediate onset of action. These are compelling numbers, though the studies lacked control groups and blinding.
Antioxidant and longevity effects: A study gave female mice monthly courses of DSIP (Deltaran preparation) subcutaneously from age 3 months until natural death. The treatment decreased spontaneous tumour incidence 2.6-fold (mainly mammary carcinomas and leukemias), reduced chromosome aberrations in bone marrow cells by 22.6%, slowed age-related loss of oestrous function, and increased maximum lifespan by 24.1%. Mean lifespan was unaffected, meaning DSIP didn't help average mice live longer but significantly extended the lives of the longest-lived ones. The mechanism appears to involve upregulation of endogenous antioxidant enzymes (SOD, catalase, ceruloplasmin, glutathione systems) and suppression of lipid peroxidation, particularly in late life when these systems naturally decline.
No sex-specific adjustment needed for most uses. The sleep, stress, and antioxidant mechanisms are not sex-dependent. The hormonal effects differ slightly, DSIP stimulates LH in both sexes but the downstream outcome is testosterone in men and progesterone/ovulation support in women. The longevity study above was done exclusively in female mice, so women have the stronger direct evidence for antitumour and geroprotective effects. There are no documented sex-based differences in dosing or side effect profiles.
Dosage:
- Standard dose: 100-300 mcg subcutaneously, 30-60 minutes before bedtime. Some protocols suggest 1-3 hours before bed to allow effects to establish more naturally
- Starting dose: Begin at 100 mcg to assess tolerance. Most people find their effective dose between 100-200 mcg
- Frequency: Daily use is possible but 3-5 times per week is more commonly recommended to reduce potential tolerance. Some users report that effects persist for multiple nights after a single dose, so as-needed use is also reasonable
- Cycle length: 4-8 weeks on, 2-4 weeks off. Some protocols extend to 12 weeks with periodic breaks. The cycling is to prevent receptor desensitisation rather than due to toxicity concerns
- Reconstitution: Use bacteriostatic water. Lyophilised powder stores at -20°C long-term. Once reconstituted, refrigerate at 2-8°C and use within 4 weeks. Avoid freeze-thaw cycles
- Rotate injection sites (abdomen, thighs, upper arms) to avoid tissue buildup from repeated injections in the same spot
Here's what you can expect:
DSIP is not a knockout sleep aid, so don't expect to feel sedated. Most people notice a subtle shift in sleep quality within the first few days, falling asleep more easily and waking less during the night. The more meaningful improvements in deep sleep duration and recovery quality tend to build over 1-2 weeks of consistent use. If your sleep issues are stress-driven (racing mind, cortisol-mediated waking at 2-3am), you may notice improvements sooner because of the HPA axis modulation. Morning grogginess is rare at appropriate doses but can happen if you dose too high or too late. Some users report more vivid dreams as slow-wave sleep increases. Recovery benefits (reduced soreness, better training readiness) follow from improved sleep quality and tend to become noticeable at the 2-3 week mark. If your sleep was already decent, you're unlikely to notice dramatic changes.
Side effects & risks:
- Headaches are the most commonly reported side effect across clinical trials. Usually mild and transient
- Morning grogginess or excessive sleepiness if the dose is too high or timing is wrong. Reduce dose by 25-50% or administer earlier in the evening
- Paradoxical insomnia has been reported at higher doses, particularly when starting too high. More is not better with this peptide. If sleep worsens, drop the dose
- Injection site reactions including redness, mild irritation, or small lumps. Standard for subcutaneous peptide injections, not specific to DSIP
- Transient blood pressure changes: one clinical trial noted moderate drops in blood pressure in some patients. If you already run low blood pressure or are on antihypertensives, monitor accordingly
- Nausea, dizziness, vertigo have been reported rarely
- DSIP has been described as "incredibly safe" in a 2001 editorial in the European Journal of Anaesthesiology, noting that no dose has ever killed an animal subject in research and no significant side effects beyond transient headache, nausea, and vertigo have been documented. That said, long-term safety data does not exist, and the FDA has flagged potential immunogenicity risk (the body mounting an immune response against the peptide)
- Drug interactions: DSIP is degraded by aminopeptidases, so it may interact with medications that inhibit or are metabolised by peptidases (e.g. ACE inhibitors like captopril). Avoid combining with sedatives, benzodiazepines, or other CNS depressants until you know how DSIP affects you individually
- Not studied in pregnancy or breastfeeding. DSIP is present in human breast milk naturally, but exogenous administration during pregnancy or lactation has not been evaluated
Blood markers
Cortisol (AM fasting) — check at baseline to establish your stress hormone status. If you're running DSIP specifically for HPA axis support or stress-related sleep issues, recheck at end of cycle to assess response.
IGF-1 — a proxy for growth hormone status. Check at baseline if you're interested in tracking GH-related benefits. Recheck at end of cycle.
Full blood count (CBC) — baseline general health marker. DSIP is well-tolerated in trials but a CBC catches anything unexpected.
Liver enzymes (ALT, AST) — baseline check. DSIP is metabolised peripherally and there's no evidence of hepatotoxicity, but standard practice for any peptide cycle.
LH, total and free testosterone (men) / LH, progesterone (women) — only if you're running DSIP partly for hormonal support. Check at baseline and end of cycle.
For most people using DSIP purely for sleep, a morning cortisol and a CBC at baseline is sufficient. Add hormonal panels if you're stacking with other peptides or tracking hormonal outcomes specifically.
Made with Bullet